tetano
Editor, Senior Moderator
Sci Rep
. 2021 Jul 2;11(1):13786.
doi: 10.1038/s41598-021-93060-8.
Single dose of multi-clade virus-like particle vaccine protects chickens against clade 2.3.2.1 and clade 2.3.4.4 highly pathogenic avian influenza viruses
Yong-Myung Kang[SUP] 1 [/SUP], Hyun-Kyu Cho[SUP] 1 [/SUP], Ju Hun Kim[SUP] 2 [/SUP], Su Jin Lee[SUP] 2 [/SUP], Seo-Jeong Park[SUP] 1 [/SUP], Do-Young Kim[SUP] 1 [/SUP], Seong Yup Kim[SUP] 1 [/SUP], Jung-Won Park[SUP] 3 [/SUP], Myoung-Heon Lee[SUP] 1 [/SUP], Min-Chul Kim[SUP] 4 [/SUP], Hyun-Mi Kang[SUP] 5 [/SUP]
Affiliations
Abstract
Virus-like particles (VLPs) are recognized as an alternative vaccine platform that provide effective protection against various highly pathogenic avian influenza viruses (HPAIVs). Here, we developed multi-clade VLPs expressing two HAs (a chimera of clade 2.3.2.1c and clade 2.3.4.4c HA) within a single vector. We then compared its protective efficacy with that of a monovalent VLP and evaluated its potency against each homologous strain. Chickens vaccinated with the multi-clade VLP shed less virus and were better protected against challenge than birds receiving monovalent vaccines. Single vaccination with a multi-clade VLP resulted in 100% survival, with no clinical symptoms and high levels of pre-challenge protective immunity (7.6-8.5 log[SUB]2[/SUB]). Moreover, the multi-clade VLP showed high productivity (128-256 HAU) both in the laboratory and on a large scale, making it cheaper than whole inactivated vaccines produced in eggs. However, the PD[SUB]50[/SUB] (protective dose 50%) of the multi-clade VLP against clades 2.3.2.1c and 2.3.4.4c was < 50 PD[SUB]50[/SUB] (28 and 42 PD[SUB]50[/SUB], respectively), and effective antibody response was maintained for 2-3 months. This multi-clade VLP protects against both clades of HPAI viruses and can be produced in high amounts at low cost. Thus, the vaccine has potential as a pandemic preparedness vaccine.
. 2021 Jul 2;11(1):13786.
doi: 10.1038/s41598-021-93060-8.
Single dose of multi-clade virus-like particle vaccine protects chickens against clade 2.3.2.1 and clade 2.3.4.4 highly pathogenic avian influenza viruses
Yong-Myung Kang[SUP] 1 [/SUP], Hyun-Kyu Cho[SUP] 1 [/SUP], Ju Hun Kim[SUP] 2 [/SUP], Su Jin Lee[SUP] 2 [/SUP], Seo-Jeong Park[SUP] 1 [/SUP], Do-Young Kim[SUP] 1 [/SUP], Seong Yup Kim[SUP] 1 [/SUP], Jung-Won Park[SUP] 3 [/SUP], Myoung-Heon Lee[SUP] 1 [/SUP], Min-Chul Kim[SUP] 4 [/SUP], Hyun-Mi Kang[SUP] 5 [/SUP]
Affiliations
- PMID: 34215796
- DOI: 10.1038/s41598-021-93060-8
Abstract
Virus-like particles (VLPs) are recognized as an alternative vaccine platform that provide effective protection against various highly pathogenic avian influenza viruses (HPAIVs). Here, we developed multi-clade VLPs expressing two HAs (a chimera of clade 2.3.2.1c and clade 2.3.4.4c HA) within a single vector. We then compared its protective efficacy with that of a monovalent VLP and evaluated its potency against each homologous strain. Chickens vaccinated with the multi-clade VLP shed less virus and were better protected against challenge than birds receiving monovalent vaccines. Single vaccination with a multi-clade VLP resulted in 100% survival, with no clinical symptoms and high levels of pre-challenge protective immunity (7.6-8.5 log[SUB]2[/SUB]). Moreover, the multi-clade VLP showed high productivity (128-256 HAU) both in the laboratory and on a large scale, making it cheaper than whole inactivated vaccines produced in eggs. However, the PD[SUB]50[/SUB] (protective dose 50%) of the multi-clade VLP against clades 2.3.2.1c and 2.3.4.4c was < 50 PD[SUB]50[/SUB] (28 and 42 PD[SUB]50[/SUB], respectively), and effective antibody response was maintained for 2-3 months. This multi-clade VLP protects against both clades of HPAI viruses and can be produced in high amounts at low cost. Thus, the vaccine has potential as a pandemic preparedness vaccine.